Tvardi Therapeutics Q3 2026: Net Loss Widens to $6.1M, Cash Falls to $22.3M

Tvardi Therapeutics, Inc. (NASDAQ: TVRD) reported a net loss of $6.1 million for the three months ended September 30, 2026, on November 13, 2026, against a $5.5 million loss a year earlier. Cash and cash equivalents stood at $22.3 million, down from $30.8 million in cash, cash equivalents and short-term investments at December 31, 2025. The clinical-stage biopharmaceutical company said its existing cash will fund planned operations into the third quarter of 2027.

Context — why this quarter matters for TVRD holders

Tvardi is a clinical-stage company with no approved product and no revenue line in its consolidated statements of operations. Every dollar of operating expense is funded from the balance sheet, which makes the cash runway the single most load-bearing number in the release. The company said its existing cash and cash equivalents will be sufficient to fund operations, as currently planned, into the third quarter of 2027.

The report frames that runway with an explicit condition. Advancing TTI-109 into ulcerative colitis, and into additional indications, remains subject to additional funding and Investigational New Drug clearance. That is the company's own characterization, not an inference, and it means the pipeline timeline and the financing calendar are now the same question.

The quarter's expense mix shifted. Research and development rose to $4.5 million from $3.6 million a year earlier, which the company attributed primarily to higher clinical costs associated with TTI-101. General and administrative expenses fell to $1.9 million from $2.3 million, which the company attributed primarily to lower professional fees. The two lines moved in opposite directions, so total operating expenses rose only modestly.

The comparable the company itself supplies is the nine-month period. Research and development for the nine months ended September 30, 2026 was $13.4 million against $12.5 million a year earlier, while general and administrative expenses were essentially flat at $6.6 million versus $6.6 million. That flatness matters: the G&A decline in the quarter is not yet a nine-month trend.

Interest income also stepped down, to $204,000 in the quarter from $411,000 a year earlier, consistent with a smaller invested balance after short-term investments were drawn to zero.

Data — what the numbers show

The balance sheet contracted. Total assets fell to $23.5 million at September 30, 2026 from $32.1 million at December 31, 2025. Total liabilities fell to $8.1 million from $11.1 million over the same span, with accounts payable dropping to $2.1 million from $3.2 million and accrued expenses to $5.9 million from $7.7 million. Total stockholders' equity declined to $15.5 million from $20.9 million.

The share count expanded sharply. Common shares issued and outstanding rose to 13,345,956 at September 30, 2026 from 9,381,344 at December 31, 2025, and additional paid-in capital rose to $145.3 million from $131.4 million. The accumulated deficit widened to $129.8 million from $110.5 million.

Metric	Q3 2026	Q3 2025
Research and development	$4.5M	$3.6M
General and administrative	$1.9M	$2.3M
Net loss	$6.1M	$5.5M
Net loss per share, basic and diluted	$(0.48)	$(0.59)

Loss per share improved even as the net loss grew, because the weighted-average share count rose to 12,653,836 from 9,377,079. On a nine-month basis, the picture inverts: net loss widened to $19.4 million from $10.9 million, and basic loss per share deteriorated to $(1.85) from $(1.62). The prior-year nine-month period included $7.2 million of other income, net, which the current period did not repeat.

Analysis — what it means for biotech small caps and TVRD

Tvardi's cash position defines its negotiating position. A company that has told investors it needs additional funding to start a Phase 1 program in ulcerative colitis is, by its own description, a candidate for a financing event before that trial begins. The share count already grew by roughly four million shares over nine months, so dilution is an established feature of the equity story rather than a hypothetical one.

The counter-argument deserves equal weight. TTI-101's Phase 1b/2 REVERT LIVER CANCER study is already funded and running, and the company expects topline data in the early first quarter of 2027. A readout is an asset that does not require new capital to reach, and positive data would change the terms on which any subsequent raise is priced.

For sector watchers, TVRD sits in the STAT3-adjacent inflammatory and oncology space, where the report itself frames STAT3 as a central mediator across signaling pathways driving immune dysregulation, inflammation, and proliferation. Peers with comparable oral small-molecule programs compete for the same specialist investor base, and clinical-stage names without revenue trade on cash runway and catalyst proximity rather than earnings.

Positioning follows that logic. Holders of clinical-stage biotech are effectively long a binary catalyst calendar and short the financing risk; the report gives both sides of that trade a date. The company did not disclose any financing terms, partner, or timeline in the release.

Outlook — what to watch next

The company named two milestones. It expects TTI-101 Phase 1b/2 hepatocellular carcinoma topline data in the early first quarter of 2027, a timing it said allows for complete cohort evaluation. It also targets initiation of a TTI-109 clinical trial in ulcerative colitis in 2027, subject to IND clearance and additional funding.

The runway statement is the level to watch. The company said existing cash funds operations into the third quarter of 2027, which places the financing window before the TTI-109 start and roughly alongside the HCC readout. Any announcement of a raise, an IND clearance, or a shift in the stated runway is the next hard datapoint.

On the clinical side, the company cited positive Phase 1 healthy volunteer results for TTI-109 reported in July, and preclinical findings published in the International Journal of Molecular Sciences showing TTI-101 reached colon tissue exposure roughly eightfold higher than in plasma in a chronic colitis model.

Frequently Asked Questions

What does Tvardi Therapeutics' cash position mean for retail investors?

Cash and cash equivalents were $22.3 million at September 30, 2026, and the company said that funds planned operations into the third quarter of 2027. Because Tvardi has no product revenue, that runway is the constraint on everything else. The company stated that advancing TTI-109 into ulcerative colitis remains subject to additional funding and IND clearance, so the runway and the pipeline timeline are linked.

Why did Tvardi's net loss per share improve while its net loss grew?

Net loss rose to $6.1 million in Q3 2026 from $5.5 million a year earlier, but basic and diluted loss per share improved to $(0.48) from $(0.59). The reason is the denominator: weighted-average common shares outstanding rose to 12,653,836 from 9,377,079. More shares absorbed a larger loss, so the per-share figure fell. Over nine months, loss per share worsened to $(1.85) from $(1.62).

What happens next for TVRD and the TTI-101 program?

Tvardi said it expects topline data from the Phase 1b/2 REVERT LIVER CANCER study of TTI-101 in hepatocellular carcinoma in the early first quarter of 2027. The study evaluates TTI-101 as monotherapy and in combination with established therapies. Separately, the company targets a 2027 start for a TTI-109 trial in ulcerative colitis, conditional on IND clearance and additional funding.

Bottom Line

Tvardi's $22.3 million cash pile buys it into the third quarter of 2027, but the TTI-109 program still needs a raise before it starts.